OVERSEA CHINESE BANKING Corp Ltd Makes New $906,000 Investment in Stryker Corporation $SYK

Posted by Geri Gentry on Aug 22nd, 2026

OVERSEA CHINESE BANKING Corp Ltd purchased a new stake in Stryker Corporation (NYSE:SYK – Free Report) during the 2nd quarter, Holdings Channel reports. The fund purchased 2,877 shares of the medical technology company’s stock, valued at approximately $906,000.

Several other large investors have also modified their holdings of the business. Sankala Group LLC purchased a new stake in Stryker in the 4th quarter valued at approximately $26,000. United Financial Planning Group LLC acquired a new stake in Stryker during the 3rd quarter valued at $27,000. Godfrey Financial Associates Inc. purchased a new position in Stryker during the fourth quarter worth $26,000. Atlas Capital Advisors Inc. acquired a new position in shares of Stryker in the fourth quarter worth $27,000. Finally, Gables Capital Management Inc. acquired a new position in shares of Stryker in the second quarter worth $25,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Up 0.7%

Shares of SYK stock opened at $329.86 on Friday. The firm’s 50-day simple moving average is $326.99 and its 200-day simple moving average is $332.64. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The firm has a market cap of $126.52 billion, a P/E ratio of 34.18, a PEG ratio of 2.09 and a beta of 0.76.

Stryker (NYSE:SYK – Get Free Report) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the previous year, the firm earned $3.13 earnings per share. Stryker’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.48%.

Insider Activity

In other news, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the sale, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This represents a 2.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 665,370 shares of company stock valued at $216,238,501 in the last ninety days. Company insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a research note on Friday, May 1st. BMO Capital Markets began coverage on shares of Stryker in a report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 target price on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. Finally, Canaccord Genuity Group lowered their price target on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Get Our Latest Analysis on SYK

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Stryker Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.